Lesley Burgess
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lesley Burgess has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Amanda Paschke
Merck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.)
1 shared publicationAmy Puenpatom
Merck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.)
1 shared publicationAngela Williams-Diaz
Merck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.)
1 shared publicationCarisa De Anda
Merck & Co., Inc., Rahway, New Jersey (M.G.J., A.P., Y.Z., H.W., A.W., M.L.B., A.P., C.D.)
1 shared publication- Elizabeth R. Duke
Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center
1 shared publication - Hong Wan
Merck & Co., Inc., Rahway, USA
1 shared publication
Latest Publications
- Open Access
- 7 June 2022
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 175 (8) , 1126-1134
Effect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19
In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk factors for progression to se... Visual Additional Clinical Benefits With Molnupiravir for COVID-19. In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in the risk for hospitalization or death in... Background: In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk factors for progr...
- 7 June 2022
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 175 (8) , 1126-1134
Open AccessEffect of Molnupiravir on Biomarkers, Respiratory Interventions, and Medical Services in COVID-19
In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk factors for progression to se... Visual Additional Clinical Benefits With Molnupiravir for COVID-19. In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in the risk for hospitalization or death in... Background: In the MOVe-OUT trial, molnupiravir showed a clinically meaningful reduction in the risk for hospitalization or death in adults with mild to moderate COVID-19 and risk factors for progr...
- Open Access
- 1 September 2011
- Published by Taylor & Francis in Open Access Journal of Clinical Trials
- p. 51
Examining the clinical trial feasibility process and its implications for a trial site
Peer reviewed article authored by (Burgess LJ, Sulzer NU). Read article or submit your manuscript for publishing.
- 1 September 2011
- Published by Taylor & Francis in Open Access Journal of Clinical Trials
- p. 51
Open AccessExamining the clinical trial feasibility process and its implications for a trial site
Peer reviewed article authored by (Burgess LJ, Sulzer NU). Read article or submit your manuscript for publishing.
- 16 February 2010
- Published by Taylor & Francis
- p. 115-133
Practice in PGCE Art & Design